Thought leadership on the clinical impact on workers' compensation and auto no-fault.
3Q 2023 Brand-Generic Pipeline
The following list represents a summary of new medications approved by the U.S. Food and Drug Administration (FDA) and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. Off-label use for the treatment of conditions outside of FDA-approved indications may not be supported by medical treatment guidelines or Optum Workers’ Compensation and Auto No-Fault. Please note this list is not all-inclusive.
|Medication description||Strength(s) and dosage form(s)||Class/Indication|
|ZavzpretTM (zavegepant)||10 mg nasal spray||Calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults|
|BrixadiTM (buprenorphine) extended-release injection for subcutaneous use||Weekly use: 8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL, and 32 mg/0.64 mL single-dose prefilled syringes Monthly use: 64 mg/0.18 mL, 96 mg/0.27 mL, and 128 mg/0.36 mL single-dose prefilled syringes||Opioid antagonist indicated for the treatment of moderate-to-severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine|
First-time generics or brand alternatives
For more information about these medications, click on the link in the medication description to visit the manufacturer’s website.
|Generic name||Brand-name||Strength(s) and dosage form(s)||Class/Indication|
|Tiotropium||Spiriva® HandiHaler®||18 mcg capsule for use with HandiHaler||Bronchodilator indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and for reducing symptoms of COPD|
If you have any questions, please contact our Clinical Services team at 1-877-275-7674 ext. 8612.
Disclaimer: The information contained herein is provided as-is for informational purposes only and does not constitute medical advice or formal utilization review. This document should not be used in place of a licensed medical practitioner’s independent medical examination, opinion or practice. Optum makes no warranties or representations as to the accuracy or effectiveness of any medical treatment guidelines, formularies or FDA-approved indications that are published after the date of this document.